ARDELYX, INC. Interest Expense Nonoperating
ARDELYX, INC. (ARDX) reported Interest Expense Nonoperating of $4.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- ARDELYX, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $4.96M, a 13.80% increase year-over-year.
- ARDELYX, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $5.60M, a 33.60% increase year-over-year.
- ARDELYX, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $5.76M, a 45.17% increase year-over-year.
- ARDELYX, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $5.80M, a 72.65% increase year-over-year.
- ARDELYX, INC. interest expense nonoperating for fiscal 2025 was $20.10M, a 54.56% increase from fiscal 2024.
- ARDELYX, INC. interest expense nonoperating for fiscal 2024 was $13.01M, a 162.75% increase from fiscal 2023.
- ARDELYX, INC. interest expense nonoperating for fiscal 2023 was $4.95M, a 45.59% increase from fiscal 2022.
- ARDELYX, INC. interest expense nonoperating for fiscal 2022 was $3.40M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.96M 10-Q · filed 2026-08-06 | $10.56M 10-Q · filed 2026-08-06 | $16.32M derived: sum of 3 quarters · filed 2026-08-06 | $22.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.60M 10-Q · filed 2026-04-30 | $11.36M derived: sum of 2 quarters · filed 2026-04-30 | $17.15M derived: sum of 3 quarters · filed 2026-04-30 | $21.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $11.55M derived: sum of 2 quarters · filed 2026-02-19 | $15.91M derived: sum of 3 quarters · filed 2026-08-06 | $20.10M 10-K · filed 2026-02-19 |
| 2025-09-30 | $5.80M 10-Q · filed 2025-10-30 | $10.15M derived: sum of 2 quarters · filed 2026-08-06 | $14.34M 10-Q · filed 2025-10-30 | $18.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.36M 10-Q · filed 2026-08-06 | $8.55M 10-Q · filed 2026-08-06 | $12.51M derived: sum of 3 quarters · filed 2026-08-06 | $15.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.19M 10-Q · filed 2026-04-30 | $8.16M derived: sum of 2 quarters · filed 2026-04-30 | $11.52M derived: sum of 3 quarters · filed 2026-04-30 | $14.84M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.32M derived: sum of 2 quarters · filed 2026-02-19 | $10.65M derived: sum of 3 quarters · filed 2026-02-19 | $13.01M 10-K · filed 2026-02-19 |
| 2024-09-30 | $3.36M 10-Q · filed 2025-10-30 | $6.68M derived: sum of 2 quarters · filed 2025-10-30 | $9.04M 10-Q · filed 2025-10-30 | $10.78M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $3.33M 10-Q · filed 2025-08-04 | $5.68M 10-Q · filed 2025-08-04 | $7.42M derived: sum of 3 quarters · filed 2026-02-19 | $8.53M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.36M 10-Q · filed 2025-05-01 | $4.10M derived: sum of 2 quarters · filed 2026-02-19 | $5.20M derived: sum of 3 quarters · filed 2026-02-19 | $6.28M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $2.85M derived: sum of 2 quarters · filed 2026-02-19 | $3.92M derived: sum of 3 quarters · filed 2026-02-19 | $4.95M 10-K · filed 2026-02-19 |
| 2023-09-30 | $1.11M 10-Q · filed 2024-10-31 | $2.18M derived: sum of 2 quarters · filed 2024-10-31 | $3.21M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $1.07M 10-Q · filed 2024-08-01 | $2.10M 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | $3.40M 10-K · filed 2025-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |